Wegovy 7.2mg Injection

Wegovy 7.2mg is a new higher-dose version of the weight loss injection Wegovy (semaglutide). It’s designed as a maintenance dose for adults who have already worked up to Wegovy’s current maximum dose of 2.4mg and may need additional support to continue losing weight or to maintain their weight loss. 

The 7.2mg dose is under regulatory review and not yet licensed for use in the UK or anywhere. As of now, 2.4mg once weekly is the highest approved dose of Wegovy for weight management.

When Wegovy treatment is stopped, weight regain can occur.

In one study, patients who discontinued semaglutide after 68 weeks regained about two-thirds of the weight they had lost within the next year².

This underscores why a maintenance strategy is needed: obesity is a long-term condition, and for some people continuing therapy (at an effective dose) may be required to maintain improvements in weight and health alongside new healthy habits. Wegovy 7.2mg may play a role in that long-term maintenance for suitable patients.

Wegovy 7.2mg works the same way as lower doses of semaglutide, by activating GLP-1 receptors to curb appetite, reduce hunger, and help control blood sugar.

Patients feel fuller sooner and for longer, which makes it easier to eat fewer calories. The difference is that the higher dose provides a stronger effect, which can result in greater weight loss for those who need it.

According to trial data, 9 out of 10 patients on 7.2mg lost more than 5% of their body weight, and over half lost more than 20%³. These outcomes indicate a powerful effect on appetite and metabolism.

If approved, it will likely be prescribed only for patients who have shown they tolerate 2.4mg well without significant side effects.

GLP-1 receptor agonists mimic a natural gut hormone (GLP-1) that signals the brain to reduce appetite and slows down digestion, which is why Wegovy needs to be increased gradually. At 7.2mg, those effects are stronger.

Patients can expect similar types of side effects as with lower doses, mainly gastrointestinal symptoms like nausea, upset stomach, or diarrhoea, which tend to occur as the dose increases.

In trials, the overall safety profile of 7.2mg was similar to 2.4mg, with mostly mild-to-moderate GI symptoms being the most common side effects.

• Slightly more patients on 7.2mg experienced nausea or digestive issues (around 70.8% on 7.2mg vs 61.2% on 2.4mg had some GI side effect)⁴.
• Serious adverse events were nearly the same for 7.2mg as 2.4mg⁴.

One other side effect noted was dysaesthesia (tingling or change in sensation) in about 23% of patients on 7.2mg, compared to 6% on the lower dose⁵. Importantly, most of these cases were mild and resolved while patients continued treatment. This suggests that although you might feel side effects a bit more strongly at first, they often subside with time as your body adjusts – just as with the lower doses.

Many members are curious when they can access this higher dose in the UK. As of December 4 2025, Wegovy 7.2mg is not yet approved in the UK.

Novo Nordisk (the manufacturer) has submitted an application to regulatory authorities, and the review is in progress. In July 2025, the company filed for approval with the European Medicines Agency (EMA) and by regulators in the UK and other countries. Regulatory approval involves evaluation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and guidance from NICE on cost-effectiveness. These processes take time – typically several months or more. After any approval, there may be additional time needed for NHS implementation and supply to ramp up.

Some UK obesity clinics and analysts expect Wegovy 7.2mg to become available privately in early to mid-2026. The exact timing will depend on regulatory approvals and supply, so this remains an estimate rather than a guarantee.

Many people ask us what the cost of Wegovy 7.2mg will be in the UK. As of now, the price for this higher dose has not been announced.

In private UK clinics, the 2.4mg dose of Wegovy typically costs in the region of £200–£300 per month, including service fees.

The 7.2mg dose contains three times more active ingredient, so it is likely to be more expensive, but official UK pricing has not yet been announced. We will know more about the cost of Wegov 7.2mg once the product is closer to launch.

For NHS patients, what matters is whether NICE finds the 7.2mg dose to be good value for money in addition to the 2.4mg dose. If NICE extends its recommendation to include 7.2mg, then the medication would be available on the NHS with the standard prescription charge, or free for those who are exempt. It will probably only be available at specialist weight loss services just like lower doses currently are. However, given the higher cost, the NHS might introduce additional criteria (for example, requiring a certain amount of weight loss on 2.4mg first, or using 7.2mg only in specialist obesity clinics).

Whether you continue on the 2.4mg dose or step up to 7.2mg in the future, Medicspot provides clinically supervised care throughout your weight loss journey.

Our service is designed to ensure that treatment with Wegovy is safe, appropriate, and effective for you as an individual. Here’s what you can expect from our care:

• Clinical review – A clinician reviews each case for appropriateness. Before prescribing Wegovy, especially at a high dose like 7.2mg, we will thoroughly evaluate your medical history, current medications, and weight management needs. We’ll make sure the treatment is suitable and that there are no contraindications.
• Safety checks – We’ll verify your medical history using your NHS Summary Care Record (SCR). This means we look at your NHS medication record (with permission) to confirm details like past medications or conditions. By doing so, we catch any potential issues. Safety is important, especially when considering a higher dose.
• Ongoing monitoring – You’ll have a dedicated health coach (like Laura) who will check in regularly. They will help track your weight changes, discuss any side effects, and provide encouragement for the lifestyle changes that accompany the injections.
• Comprehensive support – We believe successful weight loss is about more than just a jab – it’s about building healthier habits. Our Wegovy programme combines medication with behavioural support, nutrition advice, and regular follow-ups. We help you set realistic goals and overcome plateaus.
• 12 months aftercare – Even after you reach your goal weight or complete treatment, we continue to support you for a full year. This includes check-ins, guidance on tapering or maintaining your dose, and help strengthening the lifestyle habits that keep the weight off long term.

Wegovy 7.2mg may help patients who need an extra boost beyond the current doses.

With careful use, medical supervision, and holistic support, it could enable more people in the UK to achieve life-changing weight loss and health benefits.

Always consult with a healthcare professional to see if it’s appropriate for your situation, and remember that it should be used as part of a broader plan that includes diet, exercise, and behavioural changes.

¹ Novo Nordisk. Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial and 18.7% regardless of treatment adherence. GlobeNewswire. Published January 17, 2025. Last accessed December 2025. [https://www.globenewswire.com/news-release/2025/01/17/3011376/0/en/Novo-Nordisk-A-S-Semaglutide-7-2-mg-s-c-achieved-20-7-weight-loss-in-the-STEP-UP-obesity-trial-and-18-7-regardless-of-treatment-adherence.html]

² Wilding, J.P.H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism 24(8):1553–1564 (2022). Last accessed December 2025. [https://pubmed.ncbi.nlm.nih.gov/35441470/]

³ Drugs.com. Higher dose of Wegovy® (semaglutide 7.2 mg) provided average weight loss of 21% in obesity, with one-third achieving ≥25% or more. Published January 17, 2025. Last accessed December 2025. [https://www.drugs.com/clinical_trials/higher-wegovy-provided-average-weight-loss-21-obesity-third-achieving-25-more-22079.html]

⁴ Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17.

⁵ Wharton S., Lingvay I., Hjelmesæth J., et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025. PMID: 40961952. Last accessed December 2025. [https://pubmed.ncbi.nlm.nih.gov/40961952/]

This article is for general information only and should not be used for the diagnosis or treatment of medical conditions. Medic Spot Limited has used all reasonable care in compiling the information but makes no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. In the event of an emergency, please call 999 for immediate assistance.

There is no guarantee of a specific weight loss medication being prescribed. Clinicians will review your online questionnaire and will recommend the most appropriate weight loss treatments for you based on your answers. In some cases the clinicians may contact you for additional information. See our Terms of Service for more information.